Rocatinlimab, the first anti-OX40 monoclonal antibody to successfully complete a Phase III trial, has demonstrated consistent therapeutic efficacy across multiple clinical studies in patients with moderate-to-severe atopic dermatitis. This evidence concerns the gene TNFRSF4 and atopic eczema.